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Abstract
Pulmonary vascular loss is an early feature of chronic obstructive pulmonary disease. Biomarkers
of inflammation and of metabolic syndrome, predicts loss of lung function in World Trade Center
Lung Injury (WTC-LI). We investigated if other cardiovascular disease (CVD) biomarkers also
predicted WTC-LI.
This nested case-cohort study used 801 never smoker, WTC exposed firefighters with normal
pre-9/11 lung function presenting for subspecialty pulmonary evaluation (SPE) before March,
2008. A representative sub-cohort of 124/801 with serum drawn within six months of 9/11 defined
CVD biomarker distribution. Post-9/11/01 FEV1 at subspecialty exam defined cases: susceptible
WTC-LI cases with FEV1≤77% predicted (66/801) and resistant WTC-LI cases with FEV1≥107%
(68/801). All models were adjusted for WTC exposure intensity, BMI at SPE, age at 9/11, and
pre-9/11 FEV1.
Susceptible WTC-LI cases had higher levels of Apo-AII, CRP, and MIP-4 with significant RRs of
3.85, 3.93, and 0.26 respectively with an area under the curve (AUC) of 0.858. Resistant WTC-LI
cases had significantly higher sVCAM and lower MPO with RRs of 2.24, and 2.89 respectively;
AUC 0.830.
Biomarkers of CVD in serum six-month post-9/11 predicted either susceptibility or resistance to
WTC-LI. These biomarkers may define pathways producing or protecting subjects from
pulmonary vascular disease and associated loss of lung function after an irritant exposure.
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Introduction
One of the hallmarks of particulate matter (PM) exposure is systemic inflammation,
endothelial dysfunction, and subsequent end-organ damage. (1–5) Epidemiologic
investigation has documented associations between increased ambient PM, lung disease, and
cardiovascular disease (CVD). (6–12) Inflammation and remodeling are key features of
airflow obstruction in asthma and chronic obstructive pulmonary disease (COPD). (13, 14)
High ambient PM exposures significantly decrease forced expiratory volume in one second
(FEV1) even after five to seven days. (15–17) Systemic inflammation produces vascular
endothelial injury and subsequent CVD. (18–20) Recent studies associate systemic vascular
involvement with lung disease (21, 22) and prospective studies have demonstrated an
association between impaired lung function and central arterial stiffness even before the
development of CVD, with systemic inflammation contributing to this association. (23–25)
Recently, we have shown that biomarkers of inflammation (GM-CSF, MDC) and of the
metabolic syndrome, observed in serum drawn within six months of WTC exposure, predict
the post-9/11 decline in FEV1 in this cohort of WTC-exposed FDNY firefighters. (3, 17)
Utilizing a nested case-cohort design, the goal of this study is to investigate if CVD serum
biomarkers drawn within six months of 9/11/01 can predict WTC-LI in this longitudinal
well phenotyped cohort of FDNY firefighters. We hypothesized that individuals exposed to
WTC particulates who went on to develop persistent WTC-LI, would express different
levels of CVD biomarkers than those similarly exposed individuals who were resistant to
developing WTC-LI.
The collapse of the WTC exposed tens of thousands of people to extremely high PM
concentrations. Several cohorts of WTC-exposed individuals have been longitudinally
followed. Among exposed workers, volunteers, and lower Manhattan residents, abnormal
spirometry has been a common finding. (26) In rescue/recovery workers from the Fire
Department of the City of New York (FDNY), WTC exposure led to WTC lung injury
(WTC-LI) as evidenced by substantial declines in pulmonary function in the first six months
after 9/11 (at a rate twelve times greater than that found prior to 9/11) (27, 28) and these
findings persisted over the next 6.5 years. (29)
Pulmonary vascular injury occurs early in smoking related chronic obstructive lung disease
(COPD) with pulmonary perfusion abnormalities and reduced blood return to the heart
observed prior to development of abnormal FEV1. (30, 31) Similar pathophysiology likely
occurs in irritant induced COPD. Pulmonary arteriopathy was present in 58% of lung
biopsies from non-FDNY WTC exposed individuals and in 74% with constrictive




WTC exposed FDNY firefighters entered the FDNY-Medical Monitoring and Treatment
Program (MMTP) and had spirometry at medical monitoring entry (MME). (34, 35) Briefly,
FDNY Spirometry was performed according to American Thoracic Society/ European
Respiratory Society (ATS/ERS) guidelines using Portascreen Spirometry (S&M
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Instruments, Doylestown, PA). (36) In order to provide three acceptable spirograms, seated
workers wearing nose clips performed up to 8 forced expiratory maneuvers per testing
session. Subspecialty pulmonary examination (SPE) pulmonary function tests (PFTs) were
performed according to ATS/ERS guidelines using a Jaeger Masterscreen PFT System
(Viasys Healthcare, Yorba Linda, CA). All acceptable measures were expressed in absolute
values (liters) and as percent predicted of normal
The study cohort was derived from symptomatic subjects referred for SPE (N=1720)
between 10/1/2001 and 3/10/2008. (37) The baseline cohort consisted of never-smokers
(consistently reported not smoking on all health screens), male, had reliable National Health
and Nutrition Examination Survey (NHANES) normative data for predicted FEV1, had
post-9/11 FDNY PFTs within 200 days of 9/11/01 and had pre-9/11 FEV1 >75% predicted
(801/1720, 47%). All subjects signed informed Institutional Review Board approved consent
at the time of enrollment allowing analysis of their information and samples for research
(Montefiore Medical Center; #07-09-320 and New York University; #11-00439).
Cases were defined by their FEV1% Predicted at SPE using NHANES III criteria. Those
resistant to WTC-LI, were defined as being within one standard deviation (SD) of the
highest FEV1% predicted of the study cohort (N=100) had an FEV1≥107%. Those
susceptible to WTC-LI were similarly defined as being within one SD of the lowest FEV1%
predicted of the cohort (N=100), which was an FEV1≤77%. The sub-cohort controls
(N=171) were randomly selected from the study cohort after stratification based on BMI and
FEV1% Predicted at MME. Serum biomarkers were available for N=124/171 of the sub-
cohort controls, N=68/100 resistant cases, and 66/100 susceptible cases.
Demographics
Age, gender, and years of service at FDNY were obtained from the FDNY-WTC-monitoring
database. BMIs were calculated from height and weight measured at the time of MME and
SPE. Degree of exposure was self-reported at the first FDNY-WTC-monitoring and was
categorized using the FDNY-WTC Exposure Intensity Index (Arrival Time): i. Present on
the morning of 9/11/2001 ii. Arrived after noon on 9/11/2001 iii. Arrived on 9/12/2001.
Those arriving after day three were excluded from analysis as a result of their low numbers
in this sample. (3, 17)
Serum Sampling and Analysis
Blood was drawn at MME, from 10/29/2001-1/312002 for the subjects in this analysis.
Samples were allowed to stand for one hour at room temperature before being centrifuged at
1,800 g for ten minutes. Serum was stored at −80°C (Bio-Reference Laboratories, Inc.
Elmwood Park, NJ). Serum was thawed once at four degrees and assayed using CVD-1
(HCVD1-67AK), Apolipoproteins (APO-62K), and Neurodegenerative (HNDG2-36K)
panels according to manufacturer’s instructions (Millipore, Billerica, MA) on a Luminex
200IS (Luminex Corporation, Austin, TX). Data analyzed with MasterPlex QT software
(Version 1.2; MiraiBio, Inc.). Each batch of samples processed contained controls and cases
in an approximate 12/7 ratio.
Statistical Analysis
SPSS 19 (IBM, Armonk, NY) used for all database management and statistics. Demographic
information and analyte levels were compared by Mann-Whitney U or Kruskal-Wallis
where appropriate. We used logistic regression analysis to estimate the CVD biomarkers
relative risks for crude and single analyte models adjusted for the confounders of age at
9/11, BMI at SPE, exposure group, and pre-9/11 FEV1% predicted, Table 4. Relative risk
was calculated by binary logistic regression. Cases (WTC-LI susceptible or resistant) were
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compared to the sub-cohort controls as the dichotomous outcome variable and cutpoints of
analytes were used as the predictors. MPO <25th percentile, MIP-4 ≥50th percentile, CRP
≥2.45 mg/dl, and Apo-AII, sVCAM ≥75th were defined as cutpoints. (3, 38, 39) Models
were adjusted for potential confounders; BMI at SPE, exposure group as categorical
variable, age on 9/11, and FEV1% Predicted prior to 9/11 as a continuous variable. Hosmer-
Lemeshow goodness-of-fit statistic was used as a statistical test of model adequacy.
Receiver operator characteristic area under the curve (ROC AUC) was also quantified for
each final model. For all statistical tests significance was assessed by p <0.05.
Results
Demographics
We developed a sub-cohort control to represent the full spectrum of lung function response
of the baseline cohort and two case definitions represented extremes of response to WTC
dust and smoke (Figure 1). The demographics of all groups with serum available are
summarized in Table 1. The control and case groups had similar WTC exposure; time from
9/11 to MME, time from 9/11 to SPE, years of service, and age at 9/11. BMI of susceptible
cases was higher than controls or resistant cases at MME and SPE.
Lung Function
Susceptible cases had lower FEV1 and this correlated with DLCO and measures of airflow
obstruction, including methacholine and bronchodilator response, Table 2. Lung function in
resistant cases and sub-cohort controls increased from the MME to SPE (105% to 113% and
92% to 95% respectively) while the FEV1% predicted of affected cases continued to decline
between the two pulmonary function tests (79% to 72%; p<0.001 all comparisons).
CVD Biomarkers
We measured CVD serum biomarkers expressed within six months of 9/11/2001. Compared
to sub-cohort controls, cases susceptible to WTC-LI had significant elevations of
Apolipoprotein (Apo) AI (4273.98 vs. 2569.94, p=0.003), Apo AII (1830.96 vs. 845.12,
p=0.002), Apo CII (305.80 vs. 203.18, p=0.006), Apo CIII (973.58 v 600.91, p=0.005), and
Apo E (257.43 vs. 140.71, p=0.001), and significantly lower levels of Macrophage
InflammatoryProtein-4 (MIP-4) (145.28 vs. 184.68, p=0.015), Table 3A. Whereas resistant
WTC-LI cases had significantly decreased levels of Myeloperoxidase (MPO) (117.94 vs.
143.56, p=0.016) compared to sub-cohort controls, Table 3B (median concentration in ng/ml
except for CRP is in mg/dL).
Resistant WTC-LI Cases: Development of Relative Risk Models
Univariate Model—We found that MPO <25th%, sVCAM ≥75th% predicted cases
resistant to WTC-LI in both crude and confounder adjusted models. Multivariate Model. In a
multivariate model that combined sVCAM ≥1568.65 and MPO ≤105.26 both stayed
significant predictors of resistance to WTC-LI RR=2.24 (95% CI 1.07–4.70) and RR=2.89
(95% CI 1.37–7.47) respectively, Table 4. The final model for resistance to lung injury had
an AUC of 0.830 (0.774–0.887).
Susceptible WTC-LI Cases: Development of Relative Risk Models
Univariate Analysis—We found that CRP≥2.45, ApoAI, ApoAII, ApoCII, ApoCIII, and
ApoE≥75th% and MIP-4≥50% as crude value, all significantly predicted the risk of having
an FEV1≤77% at SPE in individuals who were exposed to WTC dust. CVD biomarkers
predicted the risk of WTC-LI at SPE in both crude and confounder adjusted models, Table
4.
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Multivariate Model—We then assessed the biomarkers ability in the final logistic
regression model to predict case status after adjusting for confounders. We found that a three
analyte model combining Apo AII, CRP, and MIP-4 optimally predicted the susceptible
cases with ApoAII≥1772.87 RR=3.85 (95% CI, 1.79–8.26), CRP≥2.45 mg/dL, RR=3.93
(95% CI, 1.43–10.79), and MIP-4>194.90 ng/mL, RR=0.26 (95% CI, 0.11–0.59). The final
model produced a receiver operator characteristic area under the curve (AUC) of 0.858
(0.79–0.919), Table 4. Apo-AII was used in the final model because it consistently produced
the highest RR of any Apo when combined with another Apo and ApoAII made the other
Apolipoproteins insignificant when combined together.
Discussion
We observed serum biomarkers classically associated with CVD to predict lung function
after exposure to dust and smoke at the WTC site in FDNY non-smoking firefighters with
normal pre-9/11 lung function. Firefighters with elevated sVCAM and low MPO levels
within six months of 9/11/2001 recovered lung function returning to pre-9/11 values after an
acute decline. Alternately, individuals with elevated ApoAII and CRP levels within six
months of 9/11 had significantly increased risk of developing decreased lung function over
the subsequent six years while elevated MIP-4 reduced the risk of susceptibility to decreased
lung function.
Our observation that risk factors for vascular injury are also predictors of lung dysfunction is
consistent with recent reports that perfusion abnormalities and reduced pulmonary blood
flow occur prior to development of abnormal FEV1 in smokers at risk for COPD. In other
WTC exposed cohorts pulmonary vasculopathy is a prominent feature. Vascular injury may
be a prominent feature of irritant exposure since soldiers exposed to sand and products of
combustion also had vasculopathy on pathology. CRP is known a marker of acute systemic
inflammation and CVD. (40, 41) It is biologically plausible that processes that injure
systemic arteries could also injure pulmonary arteries. There is an inverse relationship
between serum CRP and FEV1. (42) CRP levels were elevated in individuals with COPD
independent of any CVD risks. (43) Pulmonary hypertension another disease of the
pulmonary vasculature is associated with CVD biomarkers. (44) This parallels our prior
observation that dyslipidemia predicts poor outcome after WTC dust exposure. MIP-4
(CCL18) is an early promoter of regulatory T cell differentiation and may generate an anti-
inflammatory counter-regulatory response. (45, 46) Our data demonstrate that low levels of
MPO demonstrate less neutrophil activation in patients resistant to the damaging effects of
WTC dust exposure. Neutrophil activation is an important mediator of PM induced the
pulmonary and cardiovascular vascular injury. (1, 47) Taken together, the data in this and
other recent reports emphasize the need to better understand the mechanisms by which
inhaled irritants damage pulmonary vessels.
This Case-cohort study design was utilized to assess the predictive abilities of CVD
biomarkers in determining the relative risk (RR) of either being protected from or
developing WTC-LI. (48–50) Sub-cohort controls, susceptible and resistant cases were all
drawn from the larger baseline cohort. The sub-cohort controls contain an overlapping
population of those who also met case definitions. The odds ratios approximate the RR of
the biomarker-disease relationship of the larger cohort. In addition, case-cohort studies have
several advantages. First, comparing multiple case definitions to the same sub-cohort control
group facilitates the identification of biomarkers of susceptibility and resistance to WTC-LI.
Second, the case-cohort studies are cost-effective and logistically efficient since biomarkers
only needed to be assayed for a sample of the entire cohort. Lastly, the study design
minimized batch bias and freeze-thaw problems associated with biomarker discovery. (48)
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The study cohort was nested within a larger intensively evaluated, longitudinally followed
symptomatic firefighters who presented for subspecialty pulmonary evaluation prior to
March 2008. We chose to exclude ever-smokers to eliminate the confounding effect of
smoking on lung function and CVD risk. We narrowed the baseline cohort of 801 to produce
a sub-cohort control of 136 patients with serum available, a group large enough to be
representative of the baseline cohort but small enough to allow cost effective measurement
of biomarker expression. Since the control group represented the larger cohort, comparing
biomarkers expression in cases to that in the sub cohort control permitted relative risk
measures produced by the biomarkers. We used FEV1 for case definition because it is the
best single measure of lung function available on the entire FDNY cohort at each point of
interest. Cases resistant to WTC-LI were defined by FEV1 in the top 12.5 percentile while
susceptible cases were defined by FEV1 in the lowest 12.5 percentile at SPE. This cohort
had serial pulmonary function pre- and post-9/11/2001 thereby allowing us to define
resistance or susceptibility to WTC-LI after a severe irritant exposure. Another unique
aspect of the study is biomarker expression was measured within six months after 9/11/01
and prior to recovery from injury or the development of persistent WTC-LI.
Cases susceptible or resistant to WTC-LI and the sub-cohort controls experienced similar
exposure to smoke and dust, which led to declines in their FEV1 within six months post
9/11. This suggests a similar response to acute irritant exposure. However, protected cases
and cohort controls maintained normal lung function while affected cases developed
abnormal FEV1 by SPE. One explanation for this may be that the WTC-LI cases had
significantly lower pre-9/11 FEV1. Cases therefore needed a smaller relative decline to drop
below 77% post-9/11. We adjusted for this potential confounder by adding pre-9/11 FEV1 to
all models. Predictors of resistance and susceptibility were not strongly affected by pre-9/11
FEV1 demonstrating the serum biomarker effect was independent of the pre-exposure lung
function. Similarly, increased BMI is well known to be associated with reduced FEV1, but
adjusting for this potential confounder did not alter the ability of the serum biomarkers to
predict recovery or decline in lung function. This demonstrates an inflammatory process in
susceptible lung injury cases that produces persistent loss of lung function for years after the
insult. On the other hand, resistant cases showed long-term protection from WTC-LI.
There are several limitations to this study. It’s a single unique cohort of FDNY firefighters
with serum samples available from 10/29/2001-1/31/2002. This limits the generalizability of
these finding to other WTC exposed cohorts who likely include individuals with pre-existing
lung disease or other risk factors such as smoking. Definitions of susceptible and resistant
cases were based on FEV1 measured at SPE. We believe that low FEV1 is the single best
outcome measure to define lung injury in the FDNY cohort because FEV1 has been
longitudinally measured starting three years prior to 9/11/2001 and continues to be
performed at every FDNY-WTC-MMTP. However, using FEV1 as a single measure of lung
function could lead to non-differential misclassification. Since FEV1 is reduced in both
restriction and obstruction low FEV1 doesn’t distinguish between the two. In prior
investigation, we have observed that obstruction caused the vast majority of abnormal FEV1
in WTC exposed fire fighters. (37) In addition, patients with accelerated decline in FEV1
who will progress to disease but currently have a normal FEV1 will be misclassified as
controls. While misclassification may occur when using FEV1<77% as a single measure of
abnormal lung function, heterogeneity of disease(s) produced by this single measure will
bias the results toward the null. In spite of the potential for non-differential information bias,
using low FEV1 has yielded strong biomarkers-disease associations. (3, 39) Since all the
FDNY firefighters were exposed to WTC dust, we do not have unexposed control group to
compare and therefore we cannot determine if WTC exposure is necessary for the observed
effect. Replication of these findings in other longitudinally followed populations with and
without PM exposure will be important to demonstrate the generalizability of these findings.
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Utilizing a nested case-cohort design, we were able to identify CVD serum biomarkers
drawn within six months of 9/11/01 that predicted if an exposed individual was likely to
recover lung function or progress to lung disease. These biomarkers were expressed during
disease evolution and so reflect processes leading to WTC-LI susceptibility or resistance.
The observation that CVD biomarkers predict changes in lung function is consistent with a
growing body of evidence that pulmonary vascular disease occurs early in COPD. This
study emphasizes the utility of serum stored in the aftermath of a disaster. This insight on
protein expression may guide future mechanistic and therapeutic studies designed to blunt
the impact of the world wide COPD epidemic.
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Table 3
A: Values of Significant Serum Analytes in Single logistic Regression Model
Analyte# ¶ Susceptible (N=66) Controls (N=124) p+
CRP 6.28(3.28–13.16) 5.10(1.99–11.19) 0.151
MIP-4 145.28(106.56–211.25) 184.68(109.68–948.20) 0.008
Apo AI 4273.98(2039.29–6333.55) 2569.94(1833.34–4198.31) 0.003
Apo AII 1830.96(570.65–2594.51) 845.12(428.00–1730.77) 0.002
Apo CII 263.82(11.59–1794.55) 165.01(LLOD-757.13) 0.007
Apo CIII 305.80(157.92–646.63) 203.18(112.44–398.44) 0.005
Apo E 973.58(454.16–1749.37) 600.91(311.08–1058.87) 0.001
B: Values of Significant Serum Analytes in Single logistic Regression Model
Analyte# ¶ Resistant (N=68) Controls (N=124) p+
MPO 117.94(68.01–176.91) 143.56(105.26–212.31) 0.016
sVCAM 1500.83(1126.57–1808.16) 1349.97(1126.57–1568.65) 0.103
#
Expressed as Median(Inter Quartile Range);
¶
MIP-4 in ng/mL, CRP in µg/dL, Apolipoproteins in µg/mL
+
p<0.05 by Mann-Whitney U-test between Susceptible Cases and Controls
Abbreviation Dictionary: CRP: C-Reactive Protein; MIP-4: Macrophage Inhibitory Proten-4; Apo: Apolipoprotein; LLOD: Lower Limit of
Detection
#




p<0.05 by Mann-Whitney U-test between Resistant Cases and Controls
Abbreviation Dictionary: MPO: Myeloperoxidase; sVCAM: soluble Intracellular Adhesion Molecule
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